Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P, Mazzeo F
Medicine and Surgery Faculty, Operative Division of General and Oncological Surgery, "Federico II" University of Naples, Naples, Italy.
J Surg Oncol. 2000 Apr;73(4):212-8. doi: 10.1002/(sici)1096-9098(200004)73:4<212::aid-jso5>3.0.co;2-d.
Recent reports have demonstrated improvement in the 5-year actuarial survival for patients with resected ductal adenocarcinoma. The purpose of this study is to determine the factors favoring long-term survival after pancreaticoduodenectomy.
Between 1974 and 1995, 75 patients with pancreatic head carcinoma underwent pancreaticoduodenectomy in our department.
Overall postoperative mortality rate was 5. 3% and morbidity was 24%. Median survival following resection was 17 months. Estimated 1-, 2-, and 5-year survival rates were 68%, 46.7%, and 18.7%, respectively. Five-year survival was greater for node-negative than for node-positive patients (41.7% vs. 7.8%, P < 0. 001) and for smaller (<3 cm) than for larger tumors (33.3% vs. 8.8%, P < 0.006). The 5-year survival in patients with negative margins (n = 60) was 23.3%, whereas no patient with positive margins (n = 15) survived at 13 months (P < 0.001). Multivariate analysis, performed by the Cox proportional hazards model, indicated that margin status, lymph node metastasis, tumor size, and poor histological differentiation were independent predictors of poor survival.
Five-year survival for patients undergoing pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas was 18.7%. Survival was greater in the group of patients with negative lymph nodes, tumor size <3 cm, and negative margin status.
近期报告显示,接受切除的导管腺癌患者5年精算生存率有所提高。本研究旨在确定胰十二指肠切除术后有利于长期生存的因素。
1974年至1995年间,我科75例胰头癌患者接受了胰十二指肠切除术。
术后总体死亡率为5.3%,发病率为24%。切除术后的中位生存期为17个月。估计1年、2年和5年生存率分别为68%、46.7%和18.7%。淋巴结阴性患者的5年生存率高于淋巴结阳性患者(41.7%对7.8%,P<0.001),肿瘤较小(<3 cm)患者的5年生存率高于肿瘤较大患者(33.3%对8.8%,P<0.006)。切缘阴性患者(n = 60)的5年生存率为23.3%,而切缘阳性患者(n = 15)在13个月时无患者存活(P<0.001)。通过Cox比例风险模型进行的多变量分析表明,切缘状态、淋巴结转移、肿瘤大小和组织学分化差是生存不良的独立预测因素。
接受胰十二指肠切除术治疗胰腺导管腺癌患者的5年生存率为18.7%。淋巴结阴性、肿瘤大小<3 cm和切缘阴性的患者组生存率更高。